Considering Reprogenomics in the Ethical Future of Fetal Therapy Trials

Published March 8, 2022

Summary:

A major shift is occurring in reproductive genetics and genomics as a way to improve obstetric outcomes and success rates of assisted reproductive technologies. While genomics in reproductive medicine has traditionally focused on genetic screening and diagnostic testing, there is an increasing focus on developing interventions that will modify the human genome, epigenome, or microbiome. It is essential to consider how risks for the pregnant person may shift in the context of research involving genomic interventions. We must find a balance between safeguards that monitor against unbridled use of reproductive genomic modification— particularly in light of the present lack of data about outcomes for pregnant persons—and developing overly-restrictive barriers that may stand in the way of individuals’ autonomous decisions to participate in research.

Citation and link:

Considering Reprogenomics in the Ethical Future of Fetal Therapy Trials

Farrell RM, Michie M. (2022) Considering Reprogenomics in the Ethical Future of Fetal Therapy Trials. The American Journal of Bioethics 22:3, 71-73, DOI: 10.1080/15265161.2022.2027558